Female Patient, Aged 56 Years (Patient 2).

<p>Coronal (a) and transaxial (b) localizing image planned along the course of the portal vein (line). Based on these images, a phase-contrast enconding sequence was planned perpendicular to the course of the portal vein (line). c: Portal vein (arrowhead) velocity-encoded phase-contrast image. d: Portal vein (arrow) magnitude image.</p

Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.

<p>(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.</p

Venous Flow at base line.

<p>Results are expressed as mean ± SD.</p

Patients Characteristics.

<p>Patients Characteristics.</p

Baseline characteristics of cirrhotic patients treated with sorafenib.

<p> <i>ECOG, Eastern Cooperative Oncology Group Criteria Performance Status; BMI, Body Mass Index (weight/height²).</i></p><p>(a) Calculated from the regression equation: whole lean body mass (kg) = 0.30×[[skeletal muscle at L3 using CT (cm²)]+6.06]</p><p>(b) Total tissue sectional area at L3 (cm²)</p><p>(c) Lumbar tissue index: area/height (cm²/m²).</p

Study timelines.

<p>Study timelines.</p

Comparisons between patients with and without sarcopenia.

<p> <i>SD, standard deviation; ECOG, Eastern Cooperative Oncology Group Criteria Performance Status; BMI, Body Mass Index [weight(kg)/height(m)²]; BSA, Body Surface Area.</i></p><p>(d) Calculated from regression equation: whole lean body mass (kg) = 0.30×[[skeletal muscle at L3 using CT (cm²)]+6.06].</p><p>(b) Hypertension was not considered as a dose limiting toxicity.</p

Patients selection for the present study.

<p>Patients selection for the present study.</p

Clinical and biological characteristics of study group.

<p>ALP, alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; GGT, Gamma-glutamyl transpeptidase; LBM, Lean Body Mass.</p><p>Results are expressed as median [interquartile range].</p>a<p>Lean body mass was estimated by using the Green's formula <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0042875#pone.0042875-Janmahasatian1" target="_blank">[29]</a>.</p>b<p>Creatinine clearance was estimated by using Modification of Diet in Renal Disease (MDRD) formula <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0042875#pone.0042875-Levey1" target="_blank">[28]</a>.</p

Distribution of sorafenib exposure (AUC) on day 15 after treatment initiation (n = 51).

<p>AUC was normalized per 400 mg of sorafenib. The solid line represents the median. The dotted lines represent 25^th and 75^th percentiles.</p